Citations (45)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Anna Ferrari, Cecilia Rustichelli & Carlo Baraldi. (2017) Glutamate receptor antagonists with the potential for migraine treatment. Expert Opinion on Investigational Drugs 26:12, pages 1321-1330.
Read now
Read now
Ali Jazayeri & Fiona Marshall. (2015) Implications of metabotropic glutamate receptor structures for drug discovery in neurotherapeutics. Expert Review of Neurotherapeutics 15:2, pages 123-125.
Read now
Read now
Dennis Boye Larsen, Gunda Ingemann Kristensen, Vinodenee Panchalingam, Jens Christian Laursen, Jeppe Nørgaard Poulsen, Maria Skallerup Andersen, Aginsha Kandiah & Parisa Gazerani. (2014) Investigating the expression of metabotropic glutamate receptors in trigeminal ganglion neurons and satellite glial cells: implications for craniofacial pain. Journal of Receptors and Signal Transduction 34:4, pages 261-269.
Read now
Read now
Kyle A Emmitte. (2013) mGlu5 negative allosteric modulators: a patent review (2010 – 2012). Expert Opinion on Therapeutic Patents 23:4, pages 393-408.
Read now
Read now
Svein I Bekkelund & Karl B Alstadhaug. (2011) Migraine prophylactic drugs – something new under the sun?. Expert Opinion on Investigational Drugs 20:9, pages 1201-1210.
Read now
Read now
Articles from other publishers (40)
Lin Cheng, Fan Xia, Ziyan Li, Chenglong Shen, Zhiqian Yang, Hanlin Hou, Suyue Sun, Yuying Feng, Xihao Yong, Xiaowen Tian, Hongxi Qin, Wei Yan & Zhenhua Shao. (2023) Structure, function and drug discovery of GPCR signaling. Molecular Biomedicine 4:1.
Crossref
Crossref
Siyuan Shen, Chang Zhao, Chao Wu, Suyue Sun, Ziyan Li, Wei Yan & Zhenhua Shao. (2023) Allosteric modulation of G protein-coupled receptor signaling. Frontiers in Endocrinology 14.
Crossref
Crossref
Rebecca F. Budgett, Geor Bakker, Eugenia Sergeev, Kirstie A. Bennett & Sophie J. Bradley. (2022) Targeting the Type 5 Metabotropic Glutamate Receptor: A Potential Therapeutic Strategy for Neurodegenerative Diseases?. Frontiers in Pharmacology 13.
Crossref
Crossref
Anna P. Andreou. 2022. Glutamate and Neuropsychiatric Disorders. Glutamate and Neuropsychiatric Disorders
195
228
.
Kirstie A. Bennett, John A. Christopher & Benjamin G. Tehan. 2020. From Structure to Clinical Development: Allosteric Modulation of G Protein-Coupled Receptors. From Structure to Clinical Development: Allosteric Modulation of G Protein-Coupled Receptors
35
58
.
Youwen Xu & Zizhong Li. (2019) Imaging metabotropic glutamate receptor system: Application of positron emission tomography technology in drug development. Medicinal Research Reviews 39:5, pages 1892-1922.
Crossref
Crossref
David W Dodick. (2018) Migraine. The Lancet 391:10127, pages 1315-1330.
Crossref
Crossref
Joan Font, Marc López-Cano, Serena Notartomaso, Pamela Scarselli, Paola Di Pietro, Roger Bresolí-Obach, Giuseppe Battaglia, Fanny Malhaire, Xavier Rovira, Juanlo Catena, Jesús Giraldo, Jean-Philippe Pin, Víctor Fernández-Dueñas, Cyril Goudet, Santi Nonell, Ferdinando Nicoletti, Amadeu Llebaria & Francisco Ciruela. (2017) Optical control of pain in vivo with a photoactive mGlu5 receptor negative allosteric modulator. eLife 6.
Crossref
Crossref
Claudia F. Gasparini, Robert A. Smith & Lyn R. Griffiths. (2016) Genetic insights into migraine and glutamate: a protagonist driving the headache. Journal of the Neurological Sciences 367, pages 258-268.
Crossref
Crossref
Maggie W. Waung, Simon Akerman, Mark Wakefield, Charlotte Keywood & Peter J. Goadsby. (2016) Metabotropic glutamate receptor 5: a target for migraine therapy. Annals of Clinical and Translational Neurology 3:8, pages 560-571.
Crossref
Crossref
Rajapillai L. I. Pillai & Dnyanesh N. Tipre. (2016) Metabotropic glutamate receptor 5 ? a promising target in drug development and neuroimaging. European Journal of Nuclear Medicine and Molecular Imaging 43:6, pages 1151-1170.
Crossref
Crossref
Jie Fang, Xingkai An, Shuai Chen, Zhenzhen Yu, Qilin Ma & Hongli Qu. (2016) Case-control study of GRIA1 and GRIA3 gene variants in migraine. The Journal of Headache and Pain 17:1.
Crossref
Crossref
John A. ChristopherSarah J. AvesKirstie A. BennettAndrew S. DoréJames C. ErreyAli JazayeriFiona H. MarshallKrzysztof OkrasaMaria J. Serrano-VegaBenjamin G. TehanGiselle R. WigginMiles Congreve. (2015)
Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu
5
Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile)
. Journal of Medicinal Chemistry 58:16, pages 6653-6664.
Crossref
Crossref
Sajedeh Eftekhari, Christopher A. Salvatore, Sara Johansson, Tsing-bau Chen, Zhizhen Zeng & Lars Edvinsson. (2015) Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the blood–brain barrier. Brain Research 1600, pages 93-109.
Crossref
Crossref
Kirstie A Bennett, Andrew S Doré, John A Christopher, Dahlia R Weiss & Fiona H Marshall. (2015) Structures of mGluRs shed light on the challenges of drug development of allosteric modulators. Current Opinion in Pharmacology 20, pages 1-7.
Crossref
Crossref
A. Yusta Izquierdo, M.A. Cubilla Salinas, M.J. Sánchez Palomo & F. Higes Pascual. (2015) Cefalea (II). Migraña. Medicine - Programa de Formación Médica Continuada Acreditado 11:70, pages 4155-4166.
Crossref
Crossref
Amy R. Tso & Peter J. Goadsby. (2014) New Targets for Migraine Therapy. Current Treatment Options in Neurology 16:11.
Crossref
Crossref
Nabih M Ramadan. (2013) Glutamate and migraine: From Ikeda to the 21st century. Cephalalgia 34:2, pages 86-89.
Crossref
Crossref
Guiying LiMorten Jørgensen & Brian M Campbell. (2013) Metabotropic glutamate receptor 5-negative allosteric modulators for the treatment of psychiatric and neurological disorders (2009–July 2013). Pharmaceutical Patent Analyst 2:6, pages 767-802.
Crossref
Crossref
Abraham J. Nagy & Alan M. Rapoport. (2013) Update on future headache treatments. Neurological Sciences 34:S1, pages 101-108.
Crossref
Crossref
Z.A. Hughes, S.J. Neal, D.L. Smith, S.J. Sukoff Rizzo, C.M. Pulicicchio, S. Lotarski, S. Lu, J.M. Dwyer, J. Brennan, M. Olsen, C.N. Bender, E. Kouranova, T.H. Andree, J.E. Harrison, G.T. Whiteside, D. Springer, S.V. O'Neil, S.K. Leonard, L.E. Schechter, J. Dunlop, S. Rosenzweig-Lipson & R.H. Ring. (2013) Negative allosteric modulation of metabotropic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression. Neuropharmacology 66, pages 202-214.
Crossref
Crossref
Maria Osikowicz, Joanna Mika & Barbara Przewlocka. (2013) The glutamatergic system as a target for neuropathic pain relief. Experimental Physiology 98:2, pages 372-384.
Crossref
Crossref
M. Siniatchkin, M. Sendacki, F. Moeller, S. Wolff, O. Jansen, H. Siebner & U. Stephani. (2011) Abnormal Changes of Synaptic Excitability in Migraine with Aura. Cerebral Cortex 22:10, pages 2207-2216.
Crossref
Crossref
Evan E Lebovitz, Jason M Keller, Hal Kominsky, Krisztian Kaszas, Dragan Maric & Michael J Iadarola. (2012) Positive Allosteric Modulation of TRPV1 as a Novel Analgesic Mechanism. Molecular Pain 8, pages 1744-8069-8-70.
Crossref
Crossref
C. Ragginer, A. Lechner, C. Bernecker, R. Horejsi, R. Möller, M. Wallner‐Blazek, S. Weiss, F. Fazekas, R. Schmidt, M. Truschnig‐Wilders & H.‐J. Gruber. (2012) Reduced urinary glutamate levels are associated with the frequency of migraine attacks in females. European Journal of Neurology 19:8, pages 1146-1150.
Crossref
Crossref
Frederick R. Taylor, Stephen H. Landy & Robert G. Kaniecki. (2012) Abstracts and Citations. Headache: The Journal of Head and Face Pain 52:5, pages 828-839.
Crossref
Crossref
Piero Barbanti, Cinzia Aurilia, Gabriella Egeo & Luisa Fofi. (2012) Future trends in drugs for migraine prophylaxis. Neurological Sciences 33:S1, pages 137-140.
Crossref
Crossref
Bruce J. Melancon, Corey R. Hopkins, Michael R. Wood, Kyle A. Emmitte, Colleen M. Niswender, Arthur Christopoulos, P. Jeffrey Conn & Craig W. Lindsley. (2012) Allosteric Modulation of Seven Transmembrane Spanning Receptors: Theory, Practice, and Opportunities for Central Nervous System Drug Discovery. Journal of Medicinal Chemistry 55:4, pages 1445-1464.
Crossref
Crossref
Santina Chiechio & Ferdinando Nicoletti. (2012) Metabotropic glutamate receptors and the control of chronic pain. Current Opinion in Pharmacology 12:1, pages 28-34.
Crossref
Crossref
Sylvain Célanire, Guillaume Duvey, Sonia Poli & Jean-Philippe Rocher. 2012. Annual Reports in Medicinal Chemistry Volume 47. Annual Reports in Medicinal Chemistry Volume 47
71
88
.
Hartmut GöbelHartmut Göbel. 2012. Migräne. Migräne
17
348
.
Hartmut GöbelHartmut Göbel. 2012. Die Kopfschmerzen. Die Kopfschmerzen
145
381
.
Kyle A. Emmitte. (2011)
Recent Advances in the Design and Development of Novel Negative Allosteric Modulators of mGlu
5
. ACS Chemical Neuroscience 2:8, pages 411-432.
Crossref
Crossref
Jesse M. Weiss, Hermogenes N. Jimenez, Guiying Li, Myriam April, Michelle A. Uberti, Maria D. Bacolod, Robb M. Brodbeck & Dar?o Doller. (2011) 6-Aryl-3-pyrrolidinylpyridines as mGlu5 receptor negative allosteric modulators. Bioorganic & Medicinal Chemistry Letters 21:16, pages 4891-4899.
Crossref
Crossref
Song GuoL VecseiMessoud Ashina. (2011) The L-kynurenine signalling pathway in trigeminal pain processing: A potential therapeutic target in migraine?. Cephalalgia 31:9, pages 1029-1038.
Crossref
Crossref
Jes Olesen & Messoud Ashina. (2011) Emerging migraine treatments and drug targets. Trends in Pharmacological Sciences 32:6, pages 352-359.
Crossref
Crossref
Beatrix Gyetvai, Agnes Simonyi, Melinda Oros, Mariko Saito, John Smiley & Csaba Vad?sz. (2011) mGluR7 Genetics and Alcohol: Intersection Yields Clues for Addiction. Neurochemical Research 36:6, pages 1087-1100.
Crossref
Crossref
Alfred N Fonteh, Rainbow Chung, Tara L Sharma, R Danielle Fisher, Janice M Pogoda, Robert Cowan & Michael G Harrington. (2010) Cerebrospinal fluid phospholipase C activity increases in migraine. Cephalalgia 31:4, pages 456-462.
Crossref
Crossref
Frederick R. Taylor. (2011) Nutraceuticals and Headache: The Biological Basis. Headache: The Journal of Head and Face Pain 51:3, pages 484-501.
Crossref
Crossref
May Hamza & Raymond A. Dionne. (2009) 2020 foresight: Envisioning therapeutic innovations for pain. Drug Discovery Today: Therapeutic Strategies 6:3, pages 113-119.
Crossref
Crossref